6-HYDROXYDOPAMINE LESION OF THE RAT SUBSTANTIA-NIGRA - TIME-COURSE AND MORPHOLOGY OF CELL-DEATH

被引:203
|
作者
JEON, BS
JACKSONLEWIS, V
BURKE, RE
机构
[1] SEOUL NATL UNIV HOSP,DEPT NEUROL,SEOUL 110744,SOUTH KOREA
[2] COLUMBIA UNIV,COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10027
来源
NEURODEGENERATION | 1995年 / 4卷 / 02期
关键词
CELL DEATH; DOPAMINERGIC; 6-HYDROXYDOPAMINE; SILVER STAINING; SUBSTANTIA NIGRA;
D O I
10.1006/neur.1995.0016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The 6-hydroxydopamine (6-OHDA) model of nigral injury in rats has been in use as a standard animal model of parkinsonism for many years. While earlier studies established the time course for loss of catecholamine histofluorescence or tyrosine hydroxylase immunostaining in the cell bodies and terminals, these alterations in phenotypic expression do not define the time course of morphologic degeneration. We have therefore used a silver impregnation method to characterize the time course and morphology of the degeneration of neurons in the nigrostriatal system. Abundant neuronal death was observed in substantia nigra pars compacta (SNpc) as early as 12 hours after nigral 6-OHDA injection, and prior to any evidence of striatal terminal degeneration. From 1 to 7 days neuron death was accompanied by striatal fibre degeneration. After 7 days, fibre degeneration was no longer seen, but identifiable neuron death continued at low levels for as long as 31 days, and stained amorphous material was present at 60 days. The morphologic pattern of cell death in the early phase was similar to that in the late phase, and included cytoplasmic silver deposits and dark staining of the nucleolus. At no time was the morphology of apoptosis observed. We conclude that neuron death is a progressive process following 6-OHDA lesion, with similar morphology throughout the course of degeneration.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 47 条
  • [41] ASPHYCTIC LESION - PROLIFERATION OF TYROSINE HYDROXYLASE-IMMUNOREACTIVE NERVE-CELL BODIES IN THE RAT SUBSTANTIA-NIGRA AND FUNCTIONAL-CHANGES IN DOPAMINE NEUROTRANSMISSION
    BJELKE, B
    ANDERSSON, K
    OGREN, SO
    BOLME, P
    BRAIN RESEARCH, 1991, 543 (01) : 1 - 9
  • [42] Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression
    Labandeira-Garcia, JL
    Rozas, G
    Lopezmartin, E
    Liste, I
    Guerra, MJ
    EXPERIMENTAL BRAIN RESEARCH, 1996, 108 (01) : 69 - 84
  • [43] Hydrogen sulphide attenuates neuronal apoptosis of substantia nigra by re-establishing autophagic flux via promoting leptin signalling in a 6-hydroxydopamine rat model of Parkinson's disease
    Jiang, Wu
    Zou, Wei
    Hu, Min
    Tian, Qing
    Xiao, Fan
    Li, Min
    Zhang, Ping
    Chen, Yong-Jun
    Jiang, Jia-Mei
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (01) : 122 - 133
  • [44] Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion
    Timmer, Marco
    Cesnulevicius, Konstantin
    Winkler, Christian
    Kolb, Julia
    Lipokatic-Takacs, Esther
    Jungnickel, Julia
    Grothe, Claudia
    JOURNAL OF NEUROSCIENCE, 2007, 27 (03) : 459 - 471
  • [45] Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease
    Edward J. R. Fletcher
    Lawrence D. F. Moon
    Susan Duty
    BMC Neuroscience, 20
  • [46] Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease
    Fletcher, Edward J. R.
    Moon, Lawrence D. F.
    Duty, Susan
    BMC NEUROSCIENCE, 2019, 20 (01)
  • [47] The serum level of cystatin C does not predict dopaminergic cell death in substantia nigra, evidence from 6-hydroxydopamine-induced animal model of Parkinson's disease
    Golezari, Ali Sarbazi
    Haghdoost-Yazdi, Hashem
    Minaei, Azita
    PHYSIOLOGY AND PHARMACOLOGY, 2020, 24 (02): : 111 - 122